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Abstract  
Primary care in Australia is undergoing significant reform, with a particular focus on cost-effective 
tailoring of mental health care to individual needs. Link-me is testing whether a patient-completed 
Decision Support Tool (DST), which predicts future severity of depression and anxiety symptoms and 
triages individuals into care accordingly, is clinically effective and cost-effective relative to usual 
care. The trial is set in general practices, with English-speaking patients invited to complete eligibility 
screening in their general practitioner’s waiting room. Eligible and consenting patients will then 
complete the DST assessment and are randomised and stratified according to predicted symptom 
severity. Participants allocated to the intervention arm will receive feedback on DST responses, 
select treatment priorities, assess motivation to change, and receive a severity-matched treatment 
recommendation (information about and links to low intensity services for those with mild 
symptoms, or assistance from a specially trained health professional (care navigator) for those with 
severe symptoms). All patients allocated to the comparison arm will receive usual GP care plus 
attention control. Primary (psychological distress) and secondary (depression, anxiety, quality of life, 
days out of role) outcomes will be assessed at 6 and 12 months. Differences in outcome means 
between trial arms both across and within symptom severity group will be examined using intention-
to-treat analyses. Within trial and modelled economic evaluations will be conducted to determine 
the value for money of credentials of Link-me. Findings will be reported to the Federal Government 
to inform how mental health services across Australia are funded and delivered in the future. 
Keywords: Mental health, primary care, general practice, randomised controlled trial, 
stepped care, decision support tool, care navigation 
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Date and version number  
06.08.2018 Version 1 
Abbreviations 
ATAPS Access To Allied Health Psychological Services 
CPT Clinical Prediction Tool 
DST Decision Support Tool 
EAG Evaluation Advisory Group 
EQ-5D-5L Euroqol 5-dimension quality of life questionnaire (5-level version) 
GAD-2 / GAD-7 Generalised Anxiety Disorder scale (2-item / 7-item version) 
GP General Practitioner 
HREC Human Research Ethics Committee 
ITT Intent to treat 
K10 / K10+ Kessler Psychological Distress Scale (10-item / 14-item version) 
MBS Medicare Benefit Schedule 
MI Motivational interviewing 
NPT Normalisation Process Theory 
PBS Pharmaceutical Benefit Scheme 
PHN Primary Health Network 
PHQ-2 / PHQ-9 Patient Health Questionnaire (2-item / 9-item version) 
PMHC MDS Primary Mental Health Care Minimum Data Set 
QALY Quality Adjusted Life Year 
RUQ Resource Use Questionnaire 
SC Steering committee 
Background and rationale 
Psychiatric disorders are a leading cause of disability worldwide, and despite significant investment 
in their identification and treatment, the global burden of disease associated with these disorders 
continues to rise [1]. Although effective treatments exist, there is increasing recognition that some 
people who may benefit from these miss out, and others may receive treatments that are more 
intensive than required for their level of illness [2-4]. Addressing this imbalance has been the focus 
of trials of models of collaborative care and stepped care in both the UK and the US. To date, 
however, these have delivered only small to moderate gains in health outcomes in the short- to 
medium-term [5, 6]. At the same time, there is increasing recognition of the burden that 
multimorbidity places upon the individual and the health care system, but there is limited evidence 
for interventions that improve outcomes for affected individuals treated in primary care [7, 8]. 
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In Australia, efforts to reduce the burden of psychiatric disorders have centred around providing 
access to psychological services through general practitioner (GP) referral, with substantial 
investment in the Access To Allied Health Psychological Services (ATAPS; 2001 – 2016) and the Better 
Access to Psychiatrists, Psychologists and General Practitioners through the MBS initiatives [9]. 
Uptake of psychological services under these initiatives has been considerable; in 2016-17 alone, 
more than one million Australians received psychological treatment under the Better Access scheme 
[10]. Under these initiatives, treatment is limited to a maximum number of sessions per individual 
per year (10-18 depending upon the scheme) and there is the potential for both under- and over-
treatment [3].  
It has been suggested that Australia could benefit from a more targeted approach to matching the 
intensity of service provision to individual need [11]. To this end, in 2015 the Australian Government 
introduced major service delivery reforms, including an expanded role for Primary Health Networks 
(PHNs; see Box 1) in the planning and commissioning of primary mental health care services [12]. 
Specifically, PHNs were tasked with facilitating the introduction of stepped care, defined as a 
continuum of primary mental health services within a person-centred approach, where a range of 
service types are available within local regions to better match both individual and population need 
[13].  
In this context, three PHNs have been selected to work with the University of Melbourne on Link-
me, a randomised controlled trial (RCT) of a systematic approach to stepped mental health care. 
Link-me builds on over 15 years of research, including the development of a clinical prediction tool 
(CPT) from a ten year longitudinal cohort study of depression and preliminary testing of that tool in a 
systematic approach to identification of and tailored treatment for depression in the Target-D RCT 
[14-16]. Link-me uses a Decision Support Tool (DST) completed by patients in the general practice 
setting to predict the future severity of depressive and anxiety symptoms, and triage patients into 
high or low intensity care accordingly. 
Aim 
Link-me aims to determine whether systematic identification of patients’ symptom severity using a 
DST in general practice and provision of tailored treatment recommendations is clinically and cost 
effective compared to usual care.  
Method  
Trial design  
Link-me is a stratified individually randomised controlled trial, with general practice patients 
randomly allocated to receive either the trial intervention or usual care with a 1:1 ratio. Patients are 
stratified by general practice and by predicted depressive and anxiety symptom severity at three 
months, as determined by the DST. 
The DST builds on a CPT developed for the Target-D RCT which predicts the severity of depressive 
symptoms at three months [15, 16]. The Link-me DST has been adapted with advice from an Expert 
Advisory Panel to include the prediction of anxiety symptoms as well as depression, thereby 
capturing the majority of mental health presentations in the Australian population [17]. It comprises 
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23 items1 assessing current depressive symptoms, current anxiety symptoms, lifetime history of 
depression, gender, living situation, ability to manage on available income, self-rated general health, 
and presence of chronic illness that affects the ability to carry out daily activities. Two prognostic 
models embedded within the DST use participant responses to these items to predict symptom 
scores for anxiety and depression at three months. Based on their predicted score, participants are 
classified into one of three symptom severity groups (minimal/mild, moderate, and severe) and 
receive information relevant to their group and trial arm allocation (see ‘Intervention’ below). More 
information about the DST is provided in Supplementary file 1. 
This trial protocol has been developed using the SPIRIT guidelines for intervention trial designs [18]. 
Trial setting  
Link-me is set in general practices located within the three participating PHN catchment areas, 
across three states in Australia (Victoria, New South Wales and Queensland). Demographic and 
geographical characteristics of the PHNs vary; two are located in large cities and extend to outer 
urban boundaries; the third covers a large regional area. General practice sizes differ and the mix of 
staff and availability of allied health services is likely to be variable. We anticipate at least 18 
practices will participate from across the three PHNS, in order to recruit sufficient participants (see 
‘sample size’ below). 
General practices will be invited to take part in the study by a regional trial coordinator employed by 
the relevant PHN. Eligibility criteria for general practices include: 1) seeing at least 100 adults aged 
18-75 per day; 2) using patient medical records software (to enable patient records to be easily 
updated with information relevant to Link-me participation); 3) agreement for a trained health 
professional to work in the practice to provide support for patients triaged into the severe symptom 
group; and 4) agreement to follow the trial protocol. In the event of insufficient eligible practices 
being identified, criteria 1 and 2 may be relaxed to allow additional interested practices to 
participate. A representative from each practice will asked to complete a brief survey at the time of 
recruitment to allow a description of the study sites. 
Participants 
Participants in the trial will be adults recruited in the waiting room of each participating general 
practice. Eligibility for the trial will be established in a two-stage process. First, practice (e.g. 
receptionists) or trial staff (e.g. research assistants) will approach all adult patients in the waiting 
room (regardless of reason for presentation) and through a brief discussion, establish whether the 
patient is:  
 Aged 18–75 years; 
 Sufficiently proficient in English to participate; 
 Able to provide a phone number and email address; and 
 A Medicare card holder (i.e., a permanent resident of Australia and therefore eligible for 
federally funded healthcare);  
 Able to provide informed consent. 
                                                          
1 The previous CPT on which the DST was based comprised 17 items and predicted depression only. The 
additional 6 items relate to current anxiety symptoms and are included in the prognostic model for anxiety at 
three months. 
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Patients who demonstrate signs of acute health problems (e.g. vomiting or in obvious pain) will not 
excluded from the study, however, recruiters will be encouraged to consider approaching them at 
another time (e.g., on their next visit to the practice).  
All patients who indicate to the recruiter that they meet the above criteria will be invited to take 
part in the second step of the eligibility screening process. This will entail completing a brief survey 
on a hand-held tablet device. The survey will comprise a series of demographic questions as well as a 
brief assessment of current mental health need. Patients will be eligible for Link-me if they report at 
least one of the following: 
 a score of 2 or more on the 2-item version of the Patient Health Questionnaire [PHQ-2: 19]; 
 a score of 2 or more on the 2-item version of the Generalised Anxiety Disorder scale [GAD-2: 
20]; 
 current use of medication for mental health problems. 
Patients who do not meet these criteria will be exited from the survey at the point at which they are 
no longer eligible for the trial, and will see a screen thanking them for their time and requesting that 
they return the tablet device to reception. Recruiters will be trained to check in with patients who 
agree to complete the survey and offer assistance or answer questions where required. 
Consent 
Following this two stage screening process, eligible patients will receive an invitation to take part in 
Link-me. On the tablet device, they will read a plain language statement about the trial and will be 
asked to give consent to participate. The plain language statement will also advise participants that 
they will be asked for separate consent to access routinely collected administrative data about their 
use of health services and prescription medicines (for details of this data, see ‘Economic evaluation’ 
below). In Australia, individual consent is required to access this information. Consenting to provide 
access to this data is optional and will not affect an individual’s participation in the trial itself nor the 
services that they receive. Until consenting to the trial, all data entered into the tablet is 
anonymous; individuals will only be asked to provide their name and contact details if they agree to 
take part. 
Immediately after providing consent, all participants will complete baseline measures and the DST 
assessment on the tablet device. Stratification into symptom severity groups and randomisation will 
occur at the point of assessment completion. After viewing the information relevant to their 
symptom severity group and trial arm on the tablet device, all participants will be automatically sent 
an email including: a) the trial plain language statement; b) a list of community-based services and 
support lines2; and c) further details about the request to access routinely collected health service 
use data and a link to provide online consent for the Australian Government to release this data to 
the researchers.  
Intervention  
Intervention arm 
Participants randomly allocated to the intervention arm will receive [14]: 
                                                          
2 For example, Lifeline (https://www.lifeline.org.au) which provides support to people experiencing a crisis. 
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 Feedback on their DST responses (a summary of the areas in which they appear to be 
functioning well, and where their answers indicate they may be experiencing difficulties); 
 An opportunity to set mental health priorities (selecting up to two of the areas identified as 
being difficult) and reflect on current motivation to address these priorities; 
 A treatment recommendation matched to predicted symptom group (minimal/mild or 
severe), described in more detail below. 
GPs will be notified of those patients who are allocated to the intervention arm and their treatment 
recommendation. Notifications will be provided in writing by the care navigator (Box 2), a 
professional engaged specifically in the trial to communicate this information to GPs and deliver the 
intervention for participants in the severe symptom group. The care navigator will use a 
standardised template pre-populated with the patient’s details, accessed through an online 
administration portal. This will occur following the consultation so as not to distract from the reason 
for the patient’s visit, which may not be related to their mental health. The GP will be encouraged to 
discuss the participant’s treatment recommendation at his or her next consultation (although it is up 
to the GP whether or not he or she does so). This process, in combination with the person-centred 
approach to recommending treatment as part of the DST, is designed to improve workflow and 
treatment engagement. It builds on evidence showing that simply alerting the GP to a patient’s score 
on completion of a screening tool does not improve health outcomes [21, 22], and our experience in 
the Target-D trial [15]. 
Treatment recommendations for the minimal/mild symptom group 
Participants predicted to have minimal/mild symptoms of depression and anxiety in three months’ 
time and randomised to the intervention arm will be provided with low intensity service options 
across four modalities, including online, telephone, mobile app, or in person services (see example in 
Figure 1). The service options will be matched to the areas of difficulty identified in the DST and/or 
prioritised by the participant. After a review of the published evidence, service options were 
selected based on evidence of the effectiveness of the service itself (e.g. MindSpot [23]), the 
principles underpinning it (e.g. a cognitive behavioural therapy-based app), or the behaviours it 
facilitates (e.g. a local walking group was considered to encourage exercise) [24].  
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Figure 1. Example screenshot of low intensity service options for a patient who identified mood as a 
priority area [23, 25, 26]. 
 
As well as viewing their treatment recommendations on the Link-me tablet in the practice waiting 
room, participants in the minimal/mild symptom group will also receive a copy of the 
recommendation with links to the relevant services via email (attached along with the plain language 
statement to the email described above). No additional measures will be taken to encourage 
treatment adherence. Participants will be free to follow the recommendation or not, and free to 
discuss it with their GP or not.  
 
BOX 1. DEFINITIONS 
Primary health networks: Government-funded commissioning bodies established to increase the 
efficiency and effectiveness of medical services for patients (including but not limited to mental 
health services), particularly those at risk of poor health outcomes, and improve coordination of care 
to ensure patients receive the right care in the right place at the right time [27].  
Low intensity services: Mental health interventions that minimise or eliminate specialist therapist 
contact time. Low intensity services are typically low cost and can be accessed without referral; 
focus on early intervention, self-help, and skill development; may be delivered to individuals or 
groups; and may be delivered in person, over the telephone or online [28].  
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Treatment recommendations for the severe symptom group 
Participants identified as being likely to experience severe symptoms of depression or anxiety in 
three months and randomised to the intervention arm will be offered a model of clinical care 
coordination comprising care navigation, care planning and care packages aimed at accessing 
services likely to improve mental health (Box 2). This intervention is informed by the principles of 
collaborative care [5, 29-32] and informed by recognition that people in this group are often 
experiencing mental-physical multimorbidity and have multiple interacting physical, mental and 
social needs [33]. Our intervention has been designed to improve access to appropriate mental 
health treatment and to lifestyle interventions that might assist overall health. The care navigator 
role is described in full in Box 2 and involves:  
 Up to eight structured appointments with the care navigator to develop and implement a 
structured care plan to address the priorities set by the patient in the DST. Appointments 
can be conducted face to face in the practice or over the phone, depending on patient 
preference. For the majority of these eight appointments, the focus will likely be on the 
implementation of the plan, including providing support to identify and access appropriate 
services; 
 An explicit patient-centred focus, with the plan development and implementation led by the 
patient’s own priorities and goals. These may be articulated spontaneously or with 
assistance from the care navigator; 
 Access to additional funding via a ‘care package’ as described in Box 2; 
 Close collaboration between the care navigator and GP, with the care navigator acting as 
clinical companion to the GP and GP retaining final responsibility for endorsement of the 
care plan; 
 Explicit short-term involvement of the care navigator, with a clear plan for the GP and 
patient to continue working towards the patient’s goals after the end of the care navigator’s 
involvement in the patient’s care. This will generally occur after approximately three 
months, but the exact duration of care navigation is flexible and can be adapted to patient 
need. 
To encourage treatment adherence, patients in this group will receive reminders of upcoming 
appointments with their care navigator via phone, email, or SMS. Non-attenders will be similarly 
contacted to reschedule missed appointments. Care navigators will seek advice and assistance from 
GPs in encouraging patient adherence, for example discussing strategies to reach a patient who the 
care navigator has been unable to reach by phone to schedule an appointment. 
 
BOX 2: THE CARE NAVIGATOR ROLE & CARE PACKAGE OPTIONS 
Link-me care navigation is defined as a model of clinical care coordination delivered in general 
practice, in which a trained health professional (care navigator) works collaboratively with patients 
and GPs to develop and implement a structured mental health care plan that meets patient needs. 
The care navigator provides short-term assistance to identify and link patients in with appropriate 
services. 
The care navigator role has been designed to be performed by a registered health professional and 
does not require specialist mental health training. To help patients identify what they want to 
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achieve, and how, care navigators will receive training in the principles of motivational interviewing 
(MI) [34] from an internationally recognised MI trainer and qualified psychologist. Initial training 
comprises a one-day face-to-face workshop on MI skills, with refresher sessions once per month (1 
hour by phone) and up to 4 times per year (up to half day face-to-face). Care navigators will also be 
provided with written MI resources to refer to as needed. 
Care navigators will have access to a secure online administration portal to support their work with 
the patients in the severe symptom group. The portal will auto-populate with patients completing 
the DST in real time, providing care navigators with contact details and DST results for patients 
allocated to the care navigation intervention. In appointments with patients, care navigators will be 
able to use the portal to step through the process of developing a structured plan, with prompts to 
enquire about and record the patient’s current situation and past history (including medical, social, 
and psychological factors), consider treatment preferences, check current symptoms and review DST 
responses, set treatment goals and identify actions to take, and review progress. At each 
appointment, care navigators will add to or change the plan as needed. Each update saves as a 
separate file so care navigators can review previous versions at any time. The online administration 
portal also provides access to a structured suicide risk assessment which can be used as needed. 
After each appointment care navigators will complete an appointment summary in the portal, 
recording details such as duration and modality as well as their reflections on what went well and 
the challenges they faced in the appointment. 
Importantly, the care navigator role is not one that provides mental health treatment. Rather, the 
key role of the care navigator is to act as a clinical companion to the GP and to support the patient to 
identify and access services required to improve mental health. For many patients, these services 
might include those available through existing programs and funding sources (e.g., mental health 
professionals, drug and alcohol services, pharmacists, allied health). For others, a ‘care package’ may 
be required to improve access to care. 
Care packages 
Care navigators in the Link-me trial will have access to care package funding to assist in helping 
patients access additional services that may not be currently accessible (e.g., because they are not 
commissioned by PHNs or are not Government subsidised [i.e. out of pocket cost is too high]) but 
are identified as necessary to improve the patient’s mental health outcomes. PHNs will be the fund-
holders and administrators for the care package funding, which has been allocated at an amount of 
AU$2000 per expected participant, although it can be used flexibly across the pool of participants 
receiving care navigation. Care navigators will make requests to the PHN to access care package 
funding for a participant according to a guidance document outlining how and when this funding 
may be used. Services purchased with this enhanced care package funding will typically be health 
services delivered by a clinical health professional, but may be services delivered by others as 
ancillary to formal health care. Funding may support, for example, additional or alternative 
psychological services, access to other health professionals such as exercise physiologists or 
dietitians, peer support services, vocational or educational support services, yoga or mindfulness 
courses, family support services, and other individual assistance provided through community 
support agencies. Services accessed through care packages may be either evidence-based, or 
encourage behaviours or activities which have been shown effective in managing mental health [24]. 
Out of scope are goods, inpatient care, and services funded through existing programs. Use of care 
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package funding will require GP agreement that the nominated service may improve the patient’s 
mental health. In addition, services that are not explicitly listed as in or out of scope in the written 
guidance provided to care navigators will be discussed with the National Trial Coordinator and/or 
Department of Health project team prior to implementation. 
 
Comparison arm 
Participants predicted to have minimal/mild or severe symptoms at three months and randomly 
allocated to the comparison arm will continue to receive usual care from their GP. After completing 
the DST assessment, participants in this arm will receive some attention control in the form of a 
prompt on the tablet device to speak with their GP regarding any concerns they have, and the email 
described above containing a list of contacts for community-based resources and services. 
Moderate symptom group 
Participants whose scores fall between the cut-offs for minimal/mild and severe groups (i.e., those 
with moderate symptoms) will not be randomised as they are considered to be appropriately served 
by the existing mental health service options available via their GP. After participants in this group 
complete the DST assessment they will be prompted to discuss any concerns about their mental 
health with their GP and provided with a list of contacts for community-based resources and services 
via email as described above. While not a focus of this trial, they will be asked to complete outcome 
assessments at follow-up as per randomised participants, to inform further validation of the DST 
algorithm.  
Modifications and concomitant care 
The trial interventions are flexible by design and no substantive modifications are anticipated. 
Patients in both the minimal/mild and severe intervention groups will be free to take up their 
treatment recommendation or not, and may discontinue treatment at any time. For patients 
allocated to the care navigation intervention, care navigators will document reasons for 
discontinuation where known, in order to inform the embedded process evaluation. 
All participants, regardless of trial arm allocation and predicted symptom severity group will be free 
to continue any treatment they were receiving at entry to the trial, including both pharmacological 
and psychological interventions. Data collection procedures will include assessment of concomitant 
care before, during, and after the intervention phase of the trial. Additionally, for patients in the 
severe symptom intervention group, concomitant care will be identified and recorded by care 
navigators as part of the care navigation process. 
Allocation and blinding 
Randomisation will be triggered automatically within the trial’s online administration portal, after 
the participant has provided consent and completed the DST assessment, ensuring allocation 
concealment and minimising reporting and selection bias. The allocation sequence will be computer 
generated consecutively, using a biased coin algorithm [35].  
Individuals will be randomised instead of general practices for two key reasons. First, the 
intervention will be delivered at the individual level rather than the practice level. Second, the risk of 
contamination (i.e., participants in the comparison arm receiving a dose of the intervention) will be 
low because a) no one involved in patient recruitment or intervention delivery will have access to 
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the allocation schedule; and b) both GPs and care navigators will only be informed of participants 
allocated to the intervention arm: 
 Severe symptom group: GPs will be unable to refer patients to the care navigator. They will 
not receive training in care navigation or have access to care packages, and will therefore be 
unable to deliver this model of care themselves,. Our experience using this approach in 
Target-D found that GPs are only aware of the patients receiving contact from the care 
navigator, are unable to estimate how many of their patients may be involved in the trial, 
and indicate that they have not altered their approach to care for patients not receiving care 
navigation;  
 Minimal/mild symptom group: Participants will be recommended to access services based 
outside the practice, reducing the potential for practice-based contamination. We note 
however that the services recommended to this group are publicly available and may also be 
accessed by participants in the comparison arm as part of usual care. In follow-up 
assessments we will assess the number of participants in both arms who access these 
services. 
Participants cannot be blinded to their treatment allocation due to the design of the intervention. 
Staff involved in participant recruitment may be unblinded if, upon completing the DST, participants 
mention to the recruiter the information displayed on the tablet. However as above, recruitment 
staff will not be able to use this information to influence future allocations. Finally, all trial analyses 
will be conducted by statisticians blinded to participants’ allocation. However in order to support the 
process evaluation, relevant members of the research team will be partially unblinded and have 
access to care navigation information entered into the online portal. 
Outcomes  
Outcomes are assessed at trial enrolment and at 6 and 12 months after DST completion (Table 1).  
Table 1. Schedule of participant completed assessments  
 Enrolment 6 months 12 months 
Demographics ●   
Psychological distress and days out of role (K10+) ● ● ● 
Depression (PHQ-9) ● ● ● 
Anxiety (GAD-7) ● ● ● 
Quality of life (EQ-5D-5L) ● ● ● 
Health service use (RUQ) a ● ● 
a
In order to minimise participant burden, the RUQ is not administered at baseline. Instead, health service use at this 
timepoint is assessed using a general item on the K10+ and routinely collected government data about health service use 
(e.g. appointments and referrals) for those who consent, assuming that most highly used services are captured in these 
datasets.  
Primary outcome  
The primary outcome is the difference in mean psychological distress scores between the 
intervention and comparison arms at arms at 6 months. Psychological distress will be assessed using 
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the 14 item version of the Kessler Psychological Distress Scale [K10+: 36]. The K10+ is an extension of 
the standard 10 item scale (the K10) which asks respondents to indicate how often in the past 4 
weeks they have experienced certain symptoms (e.g., nervousness, hopelessness, fatigue, agitation, 
and depressed mood), using a 5-point Likert scale (where 1 = ‘not at all’ and 5 = ‘all the time’). The 
additional four questions ask respondents to nominate the number of days totally and partially 
unable to study or work due to symptoms reported in the previous 10 questions, number of health 
professional consultations sought as a result of these symptoms, and the extent to which physical 
health problems were the main cause of distress.  
Total scores are calculated as the sum of the standard 10 items and range from 10 to 50 (the 
additional four questions reported separately and do not contribute to the total score), with scores 
of 10-15, 16-21, 22-29, and 30-50 indicating low, moderate, high, and very high distress respectively 
[37]. The K10 has excellent internal consistency, and sensitivity and specificity in predicting formal 
psychiatric diagnosis [36]. Psychological distress was selected as the primary outcome as we 
considered a generic outcome measure more appropriate to the target population than one tied to a 
particular diagnosis, given that eligibility for the trial is not diagnosis-dependent. Further, the K10+ is 
the most widely used outcome measure in Australian primary mental health care, and in 2016 its use 
was mandated in all episodes of care delivered through PHN-commissioned services [38].  
Secondary outcomes  
Secondary outcomes include depressive symptom severity, anxiety symptom severity, and quality of 
life, and days out of role at 6 and 12 months, and the K10 at 12 months.  
Depressive symptom severity will be assessed using the 9-item version of the Patient Health 
Questionnaire [PHQ-9: 39] which assesses the presence of the nine DSM symptoms of depression 
over the last two weeks using a 4-point Likert scale (where 0 = ‘not at all’ and 3 = ‘nearly every day’). 
Total scores range from 0 to 27, with cut points of 5, 10, and 15 indicating mild, moderate, and 
severe depression, respectively [39]. The PHQ-9 is a validated diagnostic measure in primary care 
[40], with demonstrated efficacy and sensitivity as an outcome measure for treatment trials with a 
recommended Reliable Change Index [41]. 
Anxiety symptom severity will be assessed using the 7-item Generalised Anxiety Disorder scale 
[GAD-7: 42] which assesses the presence of generalised anxiety symptoms over the past 2 weeks 
using the same 4-point Likert scale as the PHQ-9. Total scores range from 0 to 21, with cut points of 
5, 10, and 15 corresponding to mild, moderate, and severe anxiety symptoms. Internal consistency 
and test-retest reliability for the GAD-7 are both excellent. It has high construct, convergent, and 
discriminant validity, and correlates well with measures of depression and functioning, and with 
other measures of anxiety [42]. 
Days out of role will be measured using two of the additional four questions included in the K10+, 
which ask respondents to nominate the number of days they were totally or partially unable to study 
or work.  
Quality of life will be assessed using the EQ-5D-5L, a self-report scale assessing health states across 
five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) [43]. 
Respondents rate the extent to which they have problems in each dimension on a 5-point scale, and 
indicate their overall health on a scale from 0 to 100. The EQ-5D-5L shows better discriminatory 
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power and convergent validity than the extensively validated EQ-5D-3L, on which the five 
dimensions are rated on a 3-point scale [44].  
Economic evaluation 
A comprehensive economic evaluation will be conducted, drawing on the EQ-5D-5L and information 
on health service use collected through:  
 A self-report resource use questionnaire (RUQ), adapted from one used previously in 
Australian trials of mental health interventions [15, 45, 46]. The RUQ assesses the nature, 
frequency and duration of use of relevant health services (including low intensity services 
such as online programs and mobile phone apps) during the past 6 months, as well as the 
impact of mental health problems on productivity. The RUQ includes both forced choice, 
multiple choice, and free text options (text and number fields); see examples in Table 2. It 
comprises 68 items in total, although the number of questions presented to each individual 
varies depending on their responses; the minimum number of items a participant may be 
asked to complete is 19. Using Table 2 as an example, a participant indicating they have not 
seen a psychologist in the past six months will not see the two follow up questions about 
where they saw the psychologist and how much they paid. 
 Where possible, information about health service use accessed from one or more of the 
following:  
o Medicare Benefits Schedule/Pharmaceutical Benefits Scheme (MBS/PBS): provides 
information on visits to health care providers, diagnostic tests, and prescription 
medications via Australia’s universal health care system. 
o Primary Mental Health Care Minimum Data Set (PMHC MDS): captures data on each 
episode of primary mental health care including the type, modality and duration of 
the service, which type of health professional it was delivered by, and consumer co-
payment (if any). PMHC M S data will only be available for the subset of 
participants who have received a mental health service commissioned by their PHN, 
and have consented to being included in the PMHC MDS. 
o headspace, the National Youth Mental Health Foundation: captures data on youth 
mental health services provided through headspace centres nationally. headspace 
data will only be available for the subset of participants who are aged 18 – 25 and 
have used headspace services.  
Table 2. Sample RUQ items 
Item type Item Response options 
Forced choice In the past six months, have you 
seen a psychologist because of 
your mental health? 
No 
Yes 
Multiple choice Where did you see the 
psychologist? 
Doctor’s room or other private practice 
General community health clinic 
Specialist community mental health clinic 
Community-based rehabilitation clinic 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Hospital outpatient clinic 
At a drug or alcohol service 
At your home 
Number On average, how much of your 
own money did you pay each time 
you saw a psychologist? 
$______ 
Free text In the past six months, what 
online therapy programs have you 
used for your mental health? 
_________________ 
 
Data collection and management 
Surveys of practice and GP characteristics will be completed in hard copy at each participating 
practice and sent to the University of Melbourne via registered post or scanned and sent via email as 
a PDF. Each practice and GP will be assigned a unique ID, and survey responses and identifying 
information will be entered into a separate electronic database and stored securely on a password-
protected University server. Any hard copy surveys provided to the University will be destroyed after 
the data have been checked, entered and cleaned. 
A purpose-built online data collection system will be used to ensure efficient and secure collection of 
participant data via self-report questionnaires. At trial enrolment, this will involve completing the 
eligibility screening questionnaire, outcome measures, and DST on the tablet device in the general 
practice waiting room. In addition to the outcome measures described above, demographic 
questions will be embedded into the questionnaires completed during the enrolment process, 
including age, gender, education and employment, identification as Aboriginal and/or Torres Strait 
Islander, language spoken at home, and reason for GP consultation.  
Data at each follow-up timepoint will be collected on the same online system used at enrolment. 
Two weeks prior to their due date for each assessment, participants will receive an automated email 
containing a link to the follow-up questionnaire, which they will be able to complete on any internet 
enabled device. 
At each time point, participant responses to validated outcome measures will be coded according to 
published protocols for each measure, as described above. To minimise missing data, answers to all 
questions on each page will be required before the individual can move on. Data integrity will be 
enforced through the use of forced or multiple-choice items wherever possible. Valid value and 
range checks will also be built in for free text fields where appropriate. A data manager blind to 
participant allocation will check all outcome data to identify and, where possible, resolve errors prior 
to analyses being conducted by the statistician.  
The online data collection system will automatically generate a unique number for each patient who 
commences the eligibility screening questionnaire, and all data related to that participant will be 
linked to this ID. Participants’ trial information will not be released outside of the trial without their 
permission, except where maintaining confidentiality endangers the health or safety of the 
participant or someone else. Within the online system, identifying information will be visible in order 
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to allow GPs to be notified of their patients’ treatment recommendation (for those allocated to the 
intervention group), delivery of the care navigation intervention (including use of care packages 
where relevant), completion of structured risk assessments where necessary, and participants to be 
contacted for reminders about survey completion at follow-up. At the end of the trial, the web 
developers will remove identifying information, leaving only the participant’s unique number, then 
download all trial data. The de-identified database will then be stored securely and backed up 
regularly on a central password-protected University system.  
Sample size  
Our primary aim is to test for a difference in mean K10 scores between the intervention and 
comparison arms at 6 months. However, we also plan to conduct secondary analyses to test the 
differences in mean K10 scores between the trial arms for the minimal/mild symptom and severe 
groups, separately. As a larger sample size will be required for the sub-group analyses than for the 
primary analysis, we first determined the sample size required for the sub group analyses. We then 
determined that power of the study to test for the primary hypothesis based on the combined 
sample size required for the sub-group analyses. 
Based on our diamond [47] and Target-D [15] studies we assume that around 15% of participants will 
fall into the moderate symptom group and be excluded from the trial analyses. Of the remainder, 
76.5% will be identified as belonging to the minimal/mild symptom group and a smaller proportion 
(23.5%) will fall into the severe symptom group. Thus, the critical calculation is the sample size in the 
severe symptom group as we estimate a smaller proportion of participants to be stratified into this 
group by the DST.  
Assuming 80% power and a 5% significance level for a two-tailed test for the sub-group analysis, we 
require 352 participants (176 per arm) in the severe symptom group to test for a standardised effect 
size of 0.3 (equivalent to a difference in means of 2.4 points on the K10). This effect size was 
selected based on previous trials of collaborative care interventions [5, 48]. For the minimal/mild 
symptom group, we anticipate a smaller effect size given that this group will have less room for 
improvement (i.e., lower K10 scores at baseline on average) and will receive less intensive 
treatment. Therefore, to detect a standardised effect size of 0.2 (equivalent to a difference in means 
of 1.6 points on the K10) we require 788 participants (394 per arm) in the minimal/mild symptom 
group. However, given the assumed unequal distribution of participants in the two symptom groups 
(76.5% vs 23.5%), it is likely the sample available for analysis will be 1,146 patients (573 per arm).  
Based on these figures, the combined sample size of 1,498 (749 per arm) will provide over 90% 
power to detect a standardised effect size of 0.17 (equivalent to a difference in means of 1.3 points 
on the K10) for the primary outcome at 6 months. This minimal effect size is conservative, and 
assumes the worst-case scenario of no difference in K10 in the minimal/mild symptom group, but a 
detectable difference in mean K10 scores between the trial arms in the severe symptom group. 
In order to allow for 50% attrition over 12 months, we aim to recruit a total sample of 2,996 patients 
at baseline. This baseline sample will comprise 704 participants (352 per trial arm) in the severe 
symptom group and 2,292 in the minimal/mild symptom group (1,146 per trial arm) (Figure 2).  
Retention  
To encourage retention at each follow-up assessment, participants will first be sent a primer 
postcard to remind them about the study and alert them to the fact that they will soon be asked to 
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complete their Link-me survey. Non-responders to the email survey will receive two email 
reminders, each a week apart, followed by up to four reminders via phone or text. Each reminder 
will also provide the option of completing the survey by telephone, in person at the participant’s 
general practice, or via a hard copy sent and returned by post. Participants who still do not complete 
the survey will be offered the option of only completing the primary outcome measure (K10+).  
At each follow-up assessment, participants who have not yet provided consent to release their 
health service use data will be provided another opportunity to do so, by either continuing to the 
consent form at the end of the online survey or clicking directly into the consent from an emailed 
link. 
Patient recruitment 
To achieve the required sample size, we anticipate that at least 78,000 patients will be invited to 
complete the eligibility screening survey in the waiting room (Figure 2). Based on our Target-D trial, 
we expect 60% of patients will complete the survey, 30% of whom will be eligible to participate in 
Link-me. Of these eligible patients, we project 25% of patients will consent to the trial and complete 
the DST. Data on the total number of patients attending each practice during the recruitment period 
will be sourced from practice software to enable the calculation of the proportion of the total 
patient population invited to participate. 
Practice (e.g. receptionists) or trial staff (e.g. research assistants) will conduct a brief eligibility 
assessment and provide a short verbal description of Link-me as well as a brochure with further 
information including details of how to contact the trial team at the University of Melbourne should 
the patient have questions. Recruiters will then provide interested and eligible patients with the 
tablet device on which to complete the screening survey. All staff involved in patient recruitment will 
receive a 90 minute power point-based training session (delivered by a regional trial coordinator or 
member of the University research team) and detailed procedures manual, both of which provide an 
overview of the trial and detailed recruitment procedures (including judging how and when to 
approach patients, capacity for consent, scripts, and FAQs). Following the powerpoint training, the 
trainer will supervise each recruiter for approximately 2-4 hours as he or she commences patient 
recruitment in the practice waiting room. Ongoing support, advice, and troubleshooting will be 
provided by trial coordinators and University staff through regular meetings and practice visits. 
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Invited to complete screening questionnaire 
(n = 78320)
Complete screening questionnaire 
(n = 46992; 60%) 
Screen as eligible to take part in trial 
(n = 14098; 30%)
Consent to take part in trial and complete DST 
(n = 3524; 25%)
Decline or ineligible 
to participate – 
Thanked for time and 
excluded
Intervention 
(n = 1498; 50%)
Minimal / mild
(n = 1146; 77%)
Severe 
(n = 352; 23%)
Moderate symptoms
(n = 529; 15%)
Comparison
(n = 1498; 50%)
Minimal / mild
(n = 1146; 77%)
Severe
(n = 352; 23%)
6-month follow-up 
(n = 1123; 75%)
12-month follow-up 
(n = 749; 50%)
Randomised
(n = 2996; 85%)
6-month follow-up
12-month follow-up
6-month follow-up 
(n = 1123; 75%)
12-month follow-up 
(n = 749; 50%)
 
Figure 2. Expected participant progression through the trial 
* Percentages for minimal/mild (76.5%) and severe (23.5%) groups are rounded to nearest whole number. 
Strategies implemented to achieve the required sample size will include PHN staff working with 
participating practices to display posters and information pamphlets throughout each practice to 
raise awareness of the trial, and conducting engagement activities (e.g. lunchtime seminars) with 
GPs and practice staff to increase buy-in to the trial. The research team will also provide ongoing 
support and training for PHN staff (including care navigators, regional trial coordinators, and staff 
involved in patient recruitment), and will distribute a monthly trial newsletter to PHNs, who will be 
encouraged to distribute to practices in their catchment. 
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Data analysis 
Descriptive statistics will be used to summarise socio-demographic and clinical characteristics of 
participants collected at baseline by trial arm and symptom severity. This will allow us to identify any 
imbalances between the two trial arms not addressed by randomisation.  
Analysis will employ an intention-to-treat (ITT) approach [49], where all individuals randomised will 
be included in the analysis by their allocated trial arm status regardless of whether they received all, 
part or none of the intended treatments. For the primary analysis, we will use linear regression to 
estimate the difference in the mean K10 scores between the intervention and comparison arms at 6 
months with adjustment for symptom severity group (minimal/mild vs. severe) and baseline K10 
scores. Multiple imputation will be used to address attrition bias. Sensitivity analyses will be done 
using complete-cases only and with further adjustment for practice effects using random-intercept 
modelling of practice. Effect sizes will be presented on their original metric (with 95% confidence 
intervals and p-values) and as standardised mean differences. 
We will also undertake sub-group analyses for the mild/minimal and severe symptom groups 
separately. For each sub-group, we will estimate differences in mean K10 scores at 6 months 
between the two arms, adjusting for baseline K10 scores and using multiple imputation. We will also 
undertake sensitivity analyses for the sub-group analyses using complete-case data and also 
adjusting for practice effects using a random intercept model. We will repeat all analyses (described 
for the primary outcome) using the 12-month K10 data and the secondary outcomes (depressive 
symptom severity, anxiety symptom severity and quality of life) measured at 6 and 12 months. We 
will also examine days out of role as a secondary outcome using negative binomial regression with 
effect sizes presented as rate ratios. In secondary analyses, we will adjust for pre-specified baseline 
participant characteristics (such as age, gender, education, Aboriginal and/or Torres Strait Islander 
status, use of medication for mental health). Sensitivity analyses using a pattern mixture model will 
be used to assess the robustness of the missing data assumption. We will also investigate the effects 
of non-compliance on the estimated treatment effects using a complier average casual effect (CACE) 
analysis [50]. A detailed statistical analysis plan will be made available prior to any statistical analysis 
of the primary and secondary outcomes. Analyses will be conducted in Stata 15.1 [51]. 
 
Economic evaluation 
The framework for analysing the economic consequences of the clinical care coordination model will 
be a full economic evaluation using both a ‘within trial’ methodology as well as economic modelling 
to evaluate the population-level costs and impacts of a potential national roll-out from the 
perspective of the health care sector although a partial societal perspective will also be adopted. The 
health sector includes cost borne by the government as a third party payer as well as out of pocket 
costs incurred by patients for the direct costs of medical care. The partial societal perspective will 
also add on any productivity impacts observed in the trial (both absenteeism and presenteeism). 
The economic evaluation will analyse data for the minimal/mild and severe symptom groups both 
separately and in tandem. It is hypothesised that the cost of providing more coordinated and 
tailored care for the severe symptom group will be offset by providing a more efficient model of care 
to participants within the minimal/mild symptoms. The within trial economic evaluation will 
consider the cost to deliver the low intensity and care navigation interventions (including the DST), 
the cost of suggested services to assist individuals as well as the cost of additional health care and 
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related resources utilised by participants during the trial and subsequent follow-up period. The DST 
costs will include development and maintenance costs. However, to avoid overestimating the per 
person costs (by assigning them only to trial participants) we will estimate the number of people 
who are likely to receive the intervention when implemented within the Australian population using 
assumptions based on the published literature.  
For the minimal/mild symptom group, the number, type and cost of low-intensity services accessed 
will be collected through the resource use questionnaire. For the severe symptom group, the cost of 
care navigators’ time will be based on an hourly wage rate plus overhead costs. The services 
recommended to the individual participants as part of care navigation will be collected within the 
trial database. These services will be costed based on the length and number of contacts with health 
professionals or when the services are outside of the health care system conservative estimates of 
cost will be sourced from reliable Australian sources.  
For both symptom severity groups, the cost of individual participants’ broader mental health related 
resource use will also be considered to evaluate any differences in overall costs and determine if 
substitution effects have occurred. Given that information on resource use will be obtained from 
several sources, we will ensure as much as possible that double counting of resources and costs does 
not occur.  
In Australia the preferred outcome measure in health economic evaluations is the quality adjusted 
life year (QALY) because cost-effectiveness ratios using QALYs have inherent value-for-money 
connotations (current evidence suggests a threshold of around AU$28,000/QALY) [52]. The 
Australian value set for the EQ-5D-5L will be used to derive utility values at each time point [53], 
although the more commonly used UK value set [54] will also be used in a sensitivity analysis. The 
utility values at each time point will then be used to calculate total QALYs for each participant using 
the area under the curve method [55]. Repeated measures ANOVA will be used to evaluate the 
change in utility values over the course of the trial between groups while generalised linear models 
will be used to compare the total QALYs between groups. Since the primary outcome is the K10 
score, this will also be utilised as an additional outcome measure in the economic analysis, referred 
to as a cost-consequence analysis.  
The economic evaluation will first measure and value any change to the use of health care resources 
over the observation period for those in the intervention and comparison arms, and then compare 
any additional costs to the additional outcomes achieved. Standard economic evaluation techniques 
including incremental analysis of mean differences and bootstrapping to determine confidence 
intervals will be used in the evaluation. If we find that there is an increased cost to providing the low 
intensity or care coordination services compared to usual practice we will also be able to estimate 
whether the incremental cost-effectiveness ratio falls below normally accepted value-for-money 
thresholds [56]. Extensive sensitivity analyses will also be undertaken to determine how robust the 
results are to some of the analytical assumptions (for example, variation in utility algorithm used and 
unit costs). A detailed economic analysis plan will be made available prior to analysis of the 
economic endpoints. 
We will then use the costs and outcomes data to evaluate the population cost-effectiveness of the 
intervention using economic modelling techniques. The modelling will incorporate two main extra 
components, the first being the costs of rolling out the Link-me interventions at an Australian 
population level – including both approaches to the mild and severe symptom severity groups. 
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Secondly, the potential longer-term health benefits (and costs) at a population level will also be 
estimated. This will be undertaken using the epidemiological literature to estimate longer term 
trajectories of severity states as well as resource use implications. The precise structure of the 
economic model will partly depend on the final trial results, particularly any heterogeneity in 
outcomes observed, but is likely to be an expected value cohort analysis rather than a 
microsimulation. The merit of alternative model structures such as a discrete event simulation will 
also be considered [57]. 
Process evaluation  
Qualitative and quantitative data will be collected throughout the trial to inform our understanding 
of what the enablers and challenges were for the implementation of the Link-me trial in general 
practices. Descriptions of the general practice context including relevant local community 
information, practice size, professional mix, co-located services and professionals, and patient flow 
will be developed from completed practice surveys and regular trial coordination meetings. This 
contextual data will be used in conjunction with data collected via semi-structured interviews with 
key stakeholders such as regional trial coordinators (n=3) and care navigators (1-2 per participating 
PHN). In addition, three focus groups are planned (one per participating PHN), in which up to ten 
GPs per group will be asked to share their views about care navigation processes and the 
experiences of having this model delivered within their practices. Where GPs may not be able to 
attend a focus group they will be provided with the opportunity to complete a telephone interview 
instead. The interview and focus group data will inform identification and evaluation of the barriers 
and enablers to implementation of the Link-me intervention to assess questions of sustainability and 
scalability. These interviews will be supplemented with further interview data collected with a sub-
group of patients allocated to the intervention arm of the trial (10 per severity group per PHN for a 
total of 30 participants in the mild symptom group and 30 in the severe symptom group). Patient 
interviews will focus on their experiences of the intervention with attention to the ways it could be 
enhanced.  
Normalisation Process Theory (NPT) will be employed as a theoretical framework for the process 
evaluation data analysis. Four main constructs underpin NPT: coherence, cognitive agreement, 
collective organisation and reflexive monitoring. Each of these constructs provides areas for 
examination in the implementation and evaluation of an intervention. The constructs are considered 
to be the ‘mechanisms by which the work of implementation is operationalised’ [58]. Coherence is 
concerned with how well an intervention is understood by the agents involved (this may be from a 
professional viewpoint or a patient viewpoint depending on the intervention and evaluation focus). 
Coherence asks how well people understand the intervention and share in its benefits? More than 
this, the construct of coherence refers to the processes and work undertaken by people to promote 
or inhibit routine embedding of a practice. Cognitive participation involves how much people 
participate in the intervention—how committed and engaged are they in intervention? Cognitive 
participation seeks to illuminate processes and work that individuals and organisations have to go 
through to enrol individuals to engage with the new practice. Collective action explores the roles, 
activities and skill sets required for the intervention including how well the intervention fits within 
overall goals and activities of an organisation and compatibility with existing work practices. The 
construct of collective action has four subcomponents related to contextual integration, relational 
integration, interactional workability and skill set workability. Reflexive monitoring involves the 
engagement in activities to appraise and monitor the intervention and its outcomes. Reflexive 
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monitoring is about informal and formal appraisal by individuals to assess advantages and 
disadvantages [59, 60]. 
To evaluate the implementation of Link-me using NPT principles, the four constructs and the 
underlying elements will be employed as a framework for analysis from trial establishment to 
completion. For example, to evaluate trial establishment, qualitative data collected via regular 
meetings, quarterly workshops and interviews conducted with key stakeholders will be analyzed for 
the ways in which the trial was understood, and the processes used to embed Link-me in PHNs and 
general practices. This will also include the assessment of the trial fit within organizational goals and 
activities, and the appraisal mechanisms available for assessment to explore advantages and 
disadvantages. The establishment data will be combined with analysis of the implementation of the 
interventions. For example, for participants allocated to the minimal/mild intervention group, 
telephone interview responses will be reviewed and analyzed for descriptions of receiving 
information for low intensity service options and how they engaged with this support. These 
descriptions will enable the research team to evaluate if there were shared understandings about 
the intervention, and the discussions about adoption (or non-adoption) of support will allow for 
exploration of cognitive participation. For care navigation, interviews and focus group transcripts will 
be reviewed for descriptions from different stakeholder groups about care navigation entailed. 
These descriptions will be compared with how they accord or otherwise with the research team’s 
description of care navigation. In this analysis, it will be possible to determine where there were 
shared understandings or differences in interpretations of care navigation. It will also be possible to 
identify references that are made by different stakeholders to the processes that might have 
enhanced or restricted the embedding of care navigation as a practice within organisations. For 
cognitive participation in care navigation, data will be reviewed to identify processes and work that 
participants refer to as strategies for the enrolment of individuals in care navigation. This analytic 
process will continue with the additional constructs of collective action and reflexive monitoring 
applied also to the interview and focus group data.      
Monitoring 
Link-me will be monitored by the trial Steering Committee (SC) and an independent Evaluation 
Advisory Group (EAG). The SC will be comprised of all named investigators, the trial coordinator, a 
biostatistician, and a health economist. The SC will meet monthly to finalise trial materials and 
procedures, monitor progress, troubleshoot any areas of concern or safety requirements, ensure 
that the trial is being conducted according to protocol, and identify additional training or support 
required by the project team. 
The EAG will comprise representatives of professional bodies (GPs, psychiatrists, psychologists, and 
mental health nurses), PHNs, and consumers and carers. It will act as a monitoring committee and 
meet biannually to monitor trial process and progress; advise on protocol modifications; and 
consider any adverse events and possible harms and the implications of these for the continuation 
of the trial. Given these terms of reference, a separate Data Monitoring Committee will not be 
established.  
Adverse events 
In light of the fact that the services recommended in the trial (both low intensity and those identified 
during care navigation) are also available to individuals outside the trial, and all participants are 
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linked in with health services, no interim analyses or auditing are planned to determine harm from 
the intervention directly.  
All participants reporting high levels of suicidal ideation in baseline or follow-up surveys (indicated 
by a response of “nearly every day” to question 9 on the PHQ-9: “thoughts that you would be better 
off dead or of hurting yourself in some way”) will be contacted by a care navigator (at baseline) or 
trained research assistant (at follow up) for a structured risk assessment, regardless of trial arm or 
symptom severity group. This will be reported as an adverse event but is unlikely to result in 
treatment discontinuation or modification. 
Up to three attempts will be made to contact participants for this risk assessment, and the GP will be 
alerted in writing (using a standardised template) if the participant is uncontactable or reports intent 
to hurt him/herself. Communication of the risk assessment outcome to the GP will be documented 
in the online data collection system. All participants triggering this risk assessment will be 
encouraged to make contact with their GP, and reminded of community-based resources such as 
Lifeline (and re-sent the contact list provided on enrolment in the trial if necessary). 
Passive surveillance of harms will also be in place throughout the trial and may be reported by 
participants or GPs (e.g. in an interview as part of the process evaluation, or by contacting the Link-
me team via the contact details on the plain language statement). Adverse events may also be 
disclosed in the context of care navigation, in which case the care navigator will record the event 
within the online administration portal and inform the trial manager. The trial manager will record 
severity, potential for the event to have been anticipated, and action taken, and report this to the SC 
and EAG. Serious adverse events will also be reported to the University of Melbourne Human 
Research Ethics Committee (HREC) and evaluated by the trial lead who is a trained clinician. 
Ethics and dissemination 
This protocol has been approved by the University of Melbourne HREC (ID: 1749832). Collection of 
routine government data within the MBS and PBS has been approved by the Commonwealth 
Department of Human Services (ID: MI8420). Collection of headspace data has been approved by 
headspace National Office, and collection of PMHC MDS data has been approved by the 
Commonwealth Department of Health. Approval from these bodies applies to all trial sites. Any 
substantive modifications to this protocol that affect the conduct or nature of the trial will be 
submitted to the responsible HREC for approval prior to implementation. 
Regardless of the magnitude or direction of effect, the results of this trial will be submitted to the 
Department of Health, with the final report due in September 2020. The trial will be reported 
following the CONSORT guidelines [61] and the process evaluation results detailed for further 
interpretation and analysis of effects. Subject to approval by the Department, the trial outcomes and 
evaluation may also be presented at relevant research conferences and as published articles in peer-
reviewed journals. Authorship eligibility guidelines at the respective institutions and for journals will 
be followed.  
The results of the trial will be communicated to participants via a trial newsletter and to the involved 
general practices via personal visits and community reports. The de-identified dataset and statistical 
code may be provided on request, with permission from the Department of Health. 
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Trial status  
Link-me was prospectively registered on the Australian and New Zealand Clinical Trials Registry 
(ACTRN 12617001333303) in September 2017. Participant recruitment commenced in November 
2017 and is anticipated to be completed in October 2018, with data collection ceasing 12 months 
later.  
Discussion 
Stepped mental health care is both recommended by clinical guidelines [24, 62, 63] and a focus of 
current policy direction in Australia [12]. However, tools to guide decisions around which ‘step’ of 
care to allocate an individual to are lacking. This is a particular problem for general practice, where 
the vast majority of mental health problems are identified and managed [64]. Our diamond study 
found that almost one quarter of patients met criteria for probable depression [47], and mental 
health concerns account for just over 12 percent of all GP encounters [65]. The sometimes 
significant work associated with assessment, treatment, and referral of these problems may impose 
a disproportionate burden on GPs’ time.  
Decision support tools completed prior to a consultation may assist GPs with the task of identifying 
the mental health needs of patients and assist patients to identify goals. By encouraging patients 
with minimal or mild symptoms to access low intensity services, it may be possible to reserve more 
intensive treatments for patients with greater needs. In Link-me, patients predicted to have severe 
symptoms are offered an intervention referred to as care navigation – support from a trained and 
registered professional to navigate the health care system and access appropriate services. Unique 
to this intervention, patients can access additional funding (via a care package) to support services 
outside the mental health system, where those services are considered essential to improving 
mental health. This novel approach aims to address the multimorbidity (mental, physical, and social) 
common to this group that presents a number of challenges to care and often results in poor clinical 
outcomes [66, 67]. 
Link-me will evaluate both the clinical effectiveness and economic value of implementing this model 
of care. We will assess the extent to which savings accrued from streaming people with mild 
symptoms to less intensive service options might offset any additional costs of care navigation and 
individually tailored care packages for people with severe symptoms. As a large-scale stratified 
individually randomised trial of a complex intervention, Link-me represents a unique opportunity to 
contribute to evidence-based mental health policy and guide the development and implementation 
of stepped care models in Australia. The trial is being undertaken with scalability in mind and 
analyses will consider the economic and service delivery implications of a national roll-out of the 
model of care it is testing. The results are planned to be reported directly to the Australian 
Government and will inform how mental health services across Australia are funded and delivered in 
the future.  
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